期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿尔茨海默病治疗药物的开发及探索

Development and exploration of drug therapy for Alzheimer's disease
原文传递
导出
摘要 阿尔茨海默病(AD)是最常见的神经系统变性疾病,也是最常见的痴呆类型。胆碱酯酶抑制剂及N-甲基-D-天冬氨酸拮抗剂对轻中度AD有一定疗效,但效果较缓和且为对症治疗,寻找更有效的治疗药物势在必行。本文重点综述AD治疗药物的研发及临床前期的靶向干预策略。 Alzheimer＇s disease （AD） is the most common central nervous system disorder-and the leading cause of dementia. Currently, drug therapy for AD with cholinesterase inhibitors or NMDA antagonists has demonstrated a mild efficacy. It is necessary to develop some more effective therapies for AD. This review focuses the R＆D of drugs for AD and the prevention for cognitively normal subjects in AD presymptomatic stages.
作者 刘桂冬 魏文石
机构地区 复旦大学附属华东医院神经内科
出处 《世界临床药物》 CAS 2014年第7期385-389,共5页 World Clinical Drug
基金 上海市科委<非药物干预轻度认知功能障碍>(课题编号:12411a8802)
关键词 阿尔茨海默病 Β-淀粉样蛋白 药物治疗 临床前期 Alzheimer＇s disease β-amyloid protein drug therapy preclinical phase
分类号 R971 [医药卫生—药品] R742 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献33

  • 1Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer's disease [J]. Arch Med Res, 2012, 43 (8) : 600-608.
  • 2Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline [J] . Ann IntemMed,201O, 153(3): 176-181.
  • 3Querfurth HW, Laf'erla FM. Alzheimer's disease [J]. N Engl J Med,2010,362(4): 329-344.
  • 4Alzheimer A, Stelzmann RA, Schnitzlein HN, et al. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Himrinde" [J]. ClinAnat, 1995,8 (6): 429-431 .
  • 5Furukawa K, Sopher BL, Rydel RE, et al. Increased activityregulating and neuroprotective efficacy of alpha-secretasederived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain[J]. J Neurochem, 1996, 67 (5): 1882-1896.
  • 6Eckman CB, Eckman EA. An update on the amyloid hypothesis [J]. Neurol Clin, 2007,25 (3): 669-682, vi.
  • 7De Strooper B, Annaert W, Cupers P, et al. A presenilin-Idependent gamma-secretase-like protease mediates release of Notch intracellular domain[J]. Nature, 1999,398 (6727): 518-522.
  • 8Corie V, van Dyck CH, Salloway S, et al. Safety andtolerability of the Y-secretaseinhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease[J]. Arch Neurol, 2012, 69(11): 1430-1440.
  • 9Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease [J] . N Engl J Med, 2013, 369 (4): 341-350.
  • 10Miku1ca JA, Nguyen V, Gajdosik DA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches [J] . J Clin Pharm Ther, 2014, 39 (I): 25-37.
世界临床药物
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部